Seven Popular Techniques to Get Traffic for Free

Posted on February 19, 2011 by admin

Receiving traffic is one of the main principal work for all web professional. What is more, you can not get traffic once and then merely pick the reimbursement. Getting traffic is an ongoing chore and you ought to be continuously doing it, if you want to catch traffic and maintain it. Here are some of the ways to get traffic for free:

1. Optimize your site for search engines
Search engines have forever been a main system to get traffic for free of cost. That is why you have to to do your homework plus optimize your site so that it ranks favorably for the key words you aim. SEO is even now the main intense way to develop traffic for free of cost and you actually need to invest some time and hard work in the optimization of your site. SEO is not that tricky.

2. Frequently renew the contents of your site. .
If you likely some shocking techniques discovered, you might be a bit disappointed. One of the primary steps in Receiving traffic for free of cost is inconsequential but most important – develop huge substance and often update it. In terms of SEO, content is the ruler. If your substance is superior and recurrently updated you will not only develop a loyal audience of persistent site visitors, who will frequently arrive to understand what is recent, but search engines will as well like your site.

3. Get advantage of social bookmarking websites.
Social bookmarking web sites (especially the main accepted amongst them) are another influential method to catch traffic for free of cost. If you want to study how to execute it, search on this area to catch vast traffic from Social Bookmarking internet sites.

4. Exploit your Twitter and Facebook accounts.
Social networks are as well a method to get traffic for free of cost. If you are well-liked on networks, such as Twitter or Facebook, the traffic you receive from there can definitely exceed the traffic from Google plus the other search engines. It is actual that building a great association of targeted followers on Twitter and supporters on Facebook uses a lot of time and effort however usually the end result is worth.

5. Receive backlinks with other internet sites in your niche. Another technique to get traffic for free of cost is from additional internet sites in your niche. Receiving backlinks among other web-sites in your niche is as well a good for SEO, particularly if you survive to obtain backlinks without the famed nofollow attribute. But even if the backlinks are nofollow (i.e. they are rubbish for SEO), they even assist to get traffic to your site. If you get by to position your link in a obvious position on a website with great volumes of traffic, you can obtain hundreds of traffic from this link alone. But, be cautious if you trade backlinks as connecting to evil neighbors can do you a lot of harm.

6. Utilize all possibility to advertise your website for free of cost. free of cost promotion is forever welcome, so don’t neglect it. There are many ways to advertise your website for free of cost and some of the main admired ones include free of cost classified advertisings, submissions to web lookup directories, inclusion in a range of listings, etc. It is genuine that not every one of the free of cost ways to advertise your website perform in a good way But if you select the exact places to advertise your website for free of cost, this can as well result in tons of traffic. Google for the term add url or add url for free to find the right directory for this .

7. Generate a free of cost merchandise or help. Content drives the majority of traffic when you recommend a little helpful. There are various types of helpful substance you can craft and they largely rely on the function of your website. You can come up with writing with tons of guidance, otherwise small recommendations but one of the main mighty ways to catch traffic is to design a free of cost product or service. After this product or use gets well-liked and people commence browsing your website, likelihood are that they will go to see the other sections of the website as well.

Posted in Biotech Stock | Tagged , | Leave a comment

Profiting from the Boom in Natural Gas Production

Posted on November 8, 2010 by admin

The production techniques developed to release natural gas from shale formations are producing what promises to be a very profitable boom in U.S. onshore oil production. The boom is just getting started in places such as the Bakken shale formation in the Williston Basin of North Dakota, Montana and the Canadian province of Saskatchewan. A year-2008 U.S. Geologic Survey report put the amount of recoverable oil in the Bakken shale formation at 3 billion to 4.3 billion barrels. That’s roughly 15% to 20% of total U.S. proven reserves. Production from the Bakken shale has gained North Dakota a slot as the fourth-largest oil-producing state.

That’s a lot of oil in terms of U.S. production, but it’s not enough to drop the global price. With oil at about $70 a barrel, producers in the Williston Basin are quite profitable.

Let us examine further into the oil shale story and ways to invest in it.

Oil Locked in the Rock

The oil industry discovered oil in the Bakken formation way back in 1951. But until the natural gas industry pioneered technology to tap natural gas trapped in dense shale formations, oil companies couldn’t get at the oil.

The Bakken formation consists of two layers of shale with a middle layer of dolomite, another sedimentary rock. The shale has natural vertical fractures, and early drilling tried to run conventional vertical wells into these fractures. That didn’t turn out to be very effective in extracting oil, because the shale swells when exposed to drilling fluids, sealing the fractures. Iron pyrite in the shales also caused irreparable well damage in some cases.

New technologies borrowed from natural gas wells in other shale formations use horizontal drilling to tap into oil. Horizontal wells can reach thousands of feet of oil reservoir rock that may be in a layer no more than 140 feet thick. Using hydraulic fracturing technology can increase the flow by creating fractures that let the oil seep toward the well.

All this certainly seems to work. For example, on Oct. 4, Brigham Exploration (BEXP, news, msgs) announced the completion of its Rough Rider Three Forks well with an early 24-hour peak flow rate of about 2,356 barrels of oil equivalent. The company has now completed 36 Bakken and Three Fork wells in North Dakota, with an average 24-hour peak flow rate of about 2,684 barrels of oil equivalent. Those are high rates of flow.

Need Plenty of  Water

This isn’t to say that everything is going to be smooth sailing in the Williston Basin for oil producers. The big problem is water — or actually, the lack of it. Producing oil from shale requires about four barrels of fresh water to produce a barrel of oil, compared with one barrel of water required from conventional sources. That requires oil producers in the Williston Basin to employ a constant caravan of trucks to supply millions of gallons to each well site, where it is then pumped down the well bore at pressures high enough to fracture the shale. The Bismarck (N.D.) Tribune estimates that producing oil and gas from the Bakken shales will use up to 5.5 billion gallons of water a year.

North Dakota isn’t exactly swimming in water. Average annual rainfall in the state ranges from 13 to 20 inches a year. That’s a lot in comparison to the 5 inches that fall in the Mojave Desert each year. It’s roughly equal to the 15 inches that fall on Los Angeles in a year. New York City gets an average of 43 inches.

Looking to Buy In

Interested in buying into the Bakken boom anyway? There are two ways to go.

First, you can buy shares of a relatively small, relatively pure play oil exploration and production company in the Williston Basin.

Brigham Exploration is an example of the kind of company I mean. As of Dec. 31, 2009, the company had 282,584 net leasehold acres in the Williston Basin. Beginning in 2007, the company shifted the majority of its drilling operations from the Anadarko Basin in west Texas and the onshore Gulf Coast to Williston. It drilled 53 wells in Williston in 2008 and 54 in 2009. Total investment in drilling, leases and seismic exploration came to $220 million through the end of 2009.

The company has only 117 million shares outstanding and a market capitalization of just $2.3 billion. Revenue came to $70 million in 2009 and is projected to hit $778 million in 2010. Projected earnings per share are 45 cents for 2010 and 80 cents for 2011. The Wall Street consensus calls for 47% average annual earnings growth over the next five years.

Other similar pure plays in oil production from the Bakken shales include Whiting Petroleum (WLL, news, msgs), with 88,000 acres in the Williston Basin and a market cap of $5.1 billion; Continental Resources (CLR, news, msgs) with leases in both the Three Forks and Middle Bakken formations and a market cap of $8.2 billion; and Oasis Petroleum (OAS, news, msgs) with a market cap of $1.95 billion. Oasis Petroleum has been public only since June 2010, but it boasts 292,000 net leasehold acres in the Williston Basin.

Second, you can buy pick-and-shovel companies — that is, shares of the companies that are leasing rigs and providing services to these producers.

The last year has seen an amazing resurgence of land-based drilling in the United States. As of the end of September 2010, the number of drilling rigs working on land in the United States and Canada had climbed by 641 to 1,625 from the end of September in 2009, according to Baker Hughes (BHI, news, msgs). Of that total, 718 rigs are working in Texas, home of the Ford, Barnett and Haynesville natural gas shales. That’s up from just 328 rigs a year ago.

Louisiana is next with 178 rigs. And North Dakota is third with 135.

Contrast that with the trend in the offshore Gulf of Mexico, where 32 drilling rigs were working before the BP disaster and 19 are working now.

Drilling and oil-services companies with good exposure to land-based U.S. drilling include Weatherford International (WFT, news, msgs), Basic Energy Services (BAS, news, msgs) and Lufkin Industries (LUFK, news, msgs).

Many of these stocks trade near 52-week highs, but that’s what happens when a boom psychology is in the saddle. A congressional investigation into high-pressure hydraulic fracturing in the natural gas shales and its effect on water supplies could put a dent in some of these stocks — if investors come to believe that congressional Democrats have the votes to enact new regulations on onshore drilling.

That might give you a chance to get in at a lower price. So might a rally in the U.S. dollar. (See my blog post on the global currency wars, “Yes, it’s a currency war, and no, no one is doing anything about it.”) Is that on your list of likely events in 2010 or 2011?

Posted in Oil and Gas | Tagged , | Leave a comment

Stock Picks from World’s Greatest Investors

Posted on September 5, 2010 by admin

It will be interesting to analyse the stock picks from world’s greatest investors of all time. These four people who’ve proved they can make good money in stocks even in difficult times. And indeed, some were more upbeat after the market’s ugly summer tumbles than they were before it—after all, their favorite stocks were cheaper.

The Four Top Investors are:

  • Warren Buffett, CEO of CEO, Berkshire Hathaway
  • Thyra Zerhusen, Chief Investment Officer, Optimum Investment Advisors
  • David Herro, Portfolio Co-Manager, Oakmark International Fund
  • Susan Byrne, Chief Investment Officer, Westwood Holdings
Posted in Investing, Saving | Tagged | Leave a comment

Top Stock Picks from Warren Buffett

Posted on September 5, 2010 by admin

Warren Buffett is World’s Greatest Investor who has proved he can make good money in stocks even in difficult times. He is investing through is investment company Berkshire Hathaway. Buffett’s 44-year investment record at the helm of Berkshire is the stuff of legend. The 20 percent–a–year increase in the company’s book value per share—the company’s assets minus its liabilities—is more than double the S&P 500′s 9.3 percent return over the same stretch. This month Buffett celebrates 80 years on this planet.

 Buffett is usually eager to buy American brands like General Electric (NYSE: GE), Coca-Cola (NYSE: KO) and Harley-Davidson (NYSE: HOG) for his investment portfolio—but when the price is right elsewhere, he’ll change direction. And as it turns out, he’s just as willing to make over his company as he is his wardrobe.

Recently Buffett successfully managed the groundbreaking $26.3 billion acquisition of Burlington Northern Santa Fe (NYSE: BNI). To help raise money for the purchase, Berkshire sold shares of long-held names like Johnson & Johnson (NYSE: JNJ), Procter & Gamble (NYSE: PG) and Kraft (NYSE: KFT). And other signs have recently emerged that Buffett is less inclined to play the market: At his 2010 annual shareholder’s meeting, Buffett and his longtime partner Charlie Munger floated the possibility of paying a dividend, a previously sacrilegious idea that would further shrink Berkshire’s pool of investable money.

Here is Buffett’s Top Stock Picks.

Buffett has sold shares of some of his favorite names over the past year, but he’s quietly bought these companies’ stock.

Republic Services (NYSE: RSG)
Fast-growing waste-management company also pays a healthy dividend.

Becton Dickinson (NYSE: BDX)
Uncertainty about health care reform made shares of this medical-device maker look cheap.

Iron Mountain (NYSE: IRM)
Information-management firm is benefiting from fears about cyber-snooping.

Tesco (Other OTC: TSCDY.PK)
UK-based 4,800-store chain has been adept at adapting to local markets worldwide—including, since 2007, in the U.S.

Posted in Investing, Saving | Tagged , | 2 Comments

No Light at The End of Tunnel

Posted on March 22, 2010 by admin

Cell Therapeutics (CTIC.O) suffered a setback on Monday as a U.S. advisory panel said the company had not collected enough data to win clearance for an experimental lymphoma drug.

Today was the doom day for may CTIC  investors.  Two decade old company had half a billion market capitalization a few days back.  

Advisers to the Food and Drug Administration, in a 9-0 vote, said the company’s single trial of pixantrone was inadequate to back marketing approval.

“I don’t see this as being a well-designed or well-executed study,” said Dr. Wyndham Wilson, a panel member and a lymphoma specialist at the National Cancer Institute.

Shares of Cell Therapeutics lost 44 cents, or 48 percent, to close at 47 cents Monday. Trading had been halted until the early afternoon. The stock has ranged between 11 cents and $2.23 over the last year. Shares had been halted ahead of the panel vote.

The panel decision makes it unlikely the FDA will approve pixantrone without additional data. The agency usually follows panel recommendations, and FDA scientists who spoke to the committee also were critical of the company’s study.

Cell Therapeutics wants to sell pixantrone under the name Pixuvri for treating non-Hodgkin’s lymphoma that has stopped responding to other treatments. The blood cancer affects about 66,000 Americans annually.

The company said pixantrone offered an effective therapy for patients whose cancer worsened after at least two prior chemotherapy regimens. Patients at that stage have no approved treatments and often live less than six months.

In the Cell Therapeutics study of 140 patients, 20 percent had a major decrease in their disease if they got pixantrone, compared to about 6 percent with a different medicine.

“It is clear to me pixantrone provides an important benefit in these very poor prognosis patients,” said Dr. John Leonard, a cancer specialist at Weill Cornell Cancer Center and a Cell Therapeutics consultant.

But FDA reviewers questioned the company’s conclusions. They said the study tested less than half the number of people originally planned and included just eight U.S. patients. The agency also said heart damage and decreased white blood cells were more common with pixantrone versus other cancer drugs.

Despite their concerns, several panel members said they saw signs the drug could be helpful and urged additional study.

“This drug has some activity. I don’t think anybody on this committee would debate that point. The population enrolled in this study, however, doesn’t reflect the U.S. population of lymphoma patients,” said Dr. Mikkael Sekeres, an oncologist at the Cleveland Clinic.

In a statement after the panel vote, Cell Therapeutics Chief Executive James Bianco said the company was “committed to working closely with the FDA to address the committee’s comments as quickly as we can.”

“We continue to believe that pixantrone should be considered as a treatment option for patients” with aggressive NHL, he said.

The FDA is scheduled to make a decision on the drug by April 23. Swiss drugmaker Novartis (NOVN.VX) has an option for a worldwide license to develop and sell the drug.

Posted in Biotech Stock | Tagged , , , , | 1 Comment

Difference Between a Debit Card And a Credit Card

Posted on March 21, 2010 by admin

While credit cards and debit cards may look almost identical, not all plastic is the same. Debit cards have different protections and uses.

It’s important to understand the difference between a debit card and a credit card. There’s a difference in how the transactions are processed and the protections offered to consumers when they use them.

While debit cards and credit cards each have advantages, each is also better suited to certain situations. And since a debit card is a direct line to your bank account, there are places where it can be wise to avoid handing it over — if for no other reason than complete peace of mind. 

Credit card offers better dispute rights, buyers protection, renters insurance etc..  So it sounds good to use credit card for large purchase of electronics goods and renting a car.

Criminals are getting better with skimmers and planting them in places you’d never suspect — like ATM machines on bank property. So take a good look at the machine or card reader the next time you use an ATM or self-check lane. Does the machine fit together well or does something look off, different or like it doesn’t quite belong?  “Make sure it doesn’t look like it’s been tampered with.”

Posted in Credit Card, Saving | Tagged , , , | Leave a comment

Top Biotech Stocks for 2010

Posted on March 14, 2010 by admin

Let us look at the years Top Biotech Stocks.  In 2010, small and mid caps along with some selected large caps should perform better. Overall sentiment towards stock market and particularly biotech remains negative, which could create an attractive entry point. We think 2010 will be a year when performance is event-driven, not earnings-driven.  Small and mid caps should continue to lead innovation in the sector, which could spark M&A activity and a favorable deal environment.

Pharma companies at the 2009 J.P. Morgan Healthcare Conference cited a willingness to do ‘more deals and bigger deals’.  This will hopefully give the required stimulus for the Biotech sector.  J.P. Morgan has released a list of Biotech stocks with “high strategic value” in 2010.

  1. Acorda Therapeutics(ACOR)
  2. AMAG Pharmaceuticals(AMAG)
  3. OSI Pharmaceuticals(OSIP)
  4. Medivation(MDVN)
  5. United Therapeutics(UTHR)
  6. Vertex Pharmaceuticals(VRTX)
  7. Human Genome Sciences(HGSI)
  8. Seattle Genetics(SGEN)
  9. Savient Pharmaceuticals(SVNT)

Lehman Brothers also issued its 2010 biotech forecast “Opportunities for the U.S. biotechnology group are selective and we tend to prefer small-mid cap stocks over large-cap stocks overall”.  Their list includes:

  1. Amylin Pharmaceuticals(AMLN)
  2. Cephalon(CEPH)
  3. Human Genome Sciences
  4. Onyx Pharmaceuticals(ONXX)
  5. Regeneron Pharmaceuticals(REGN)
Posted in Biotech Stock, Investing | Tagged , , | 1 Comment

CTIC Gets New FDA Date

Posted on March 1, 2010 by admin

New FDA date for reviewing pixantrone of Cell Therapeutics is March 22.  The earlier scheduled meeting was cancelled due to severe winter weather in February.

In advance of the postponed advisory panel meeting, the FDA issued a critical review of pixantrone, highlighting numerous concerns about pixantrone’s safety and efficacy.

Shares of Cell Therapeutics were down 10% to 60 cents Monday after auditors attached a “going concern” letter to the company’s 10-K annual report filed with the Securities and Exchange Commission Friday.  For the investor, if the drug works and gets approval, auditors concern doesn’t matter.  But what if the drug fails to get an approval?

Other drug of Opaxio as a treatment for lung cancer is irrelevant as better alternatives are already in the market.  So  Pixantrone approval is very critical to the company. 

Cell Therapeutics’ total share count reached more than 615 million at the end of January, compared to 296 million shares at the end of January 2009, according to SEC filings.  Whereas, in 2009, the top five Cell Therapeutics executives earned $32 million in total compensation, most of which came in the form of company stock awards.  A classic case of Executives feasting on investors money.

Posted in Biotech Stock, FDA News | Tagged , , , , | Leave a comment

PLX4032 Gives Hope to Cancer Patients

Posted on February 25, 2010 by admin

For the melanoma patients who signed on to try a drug known as PLX4032, the clinical trial was a last resort. Their bodies were riddled with tumours, leaving them almost certainly just months to live.

But a few weeks after taking their first dose, nearly all of them began to recover.

Lee Reyes (30) of California, who had begun using a feeding tube because of a growth pressing against his throat, bit into a cinnamon roll. Randy Williams, 46, who drove 600 miles from his home in Arkansas to the M D Anderson Cancer Center in Houston for the experimental drug, rolled out of bed. “Something’s working,” he thought, “because nothing’s hurting.

It was a sweet moment, in autumn 2008, for Dr Keith Flaherty, the University of Pennsylvania oncologist leading the drug’s first clinical trial. A new kind of cancer therapy, it was tailored to a particular genetic mutation that was driving the disease, and after six years of disappointments, his faith in the promise of such a targeted approach finally seemed borne out. His collaborators at five other major cancer centres, melanoma clinicians who had tested dozens of potential therapies for their patients with no success, were equally elated.

In a kind of pinch-me exercise, the six doctors sent one another before and after CT scans of their patients.
The trial of PLX4032 offers a glimpse at how doctors, patients and drug developers navigate a medical frontier as more drugs tailored to the genetic profile of a cancer are being widely tested on humans for the first time.

Throughout the fall, the only two patients on the trial whose tumours continued to grow were the ones who did not have the particular gene mutation for which the drug had been designed. They were removed from the trial. By late December, tumours in the 11 patients who did have the mutation had shrunk. Those involved in the trial held their collective breath waiting to see how long the remissions would last.

One of them was Mark Bunting, 52, an airline pilot from Utah. His initial scan in early October showed the cancer in his bones, an incursion considered virtually impossible to reverse. After two months on the drug, it had all but disappeared. From New York, Paul B Chapman of Memorial Sloan-Kettering Cancer Center, perhaps the most determined sceptic of the group, acknowledged, “This looks impressive.”

It was a far cry from where they had been a year earlier, when a previous incarnation of the drug had no effect. Urged on by Flaherty and Chapman, the companies that owned it had spent months devising a new formulation that could be absorbed at higher doses.

But the new drug, still in the earliest phase of testing, had to pass several more hurdles before federal regulators would determine whether it was safe and effective enough for widespread use.

In December, as the doctors added more patients to the Phase 1 trial, looking for the highest dose they could give without intolerable side effects, they scrambled to prepare slides with graphs and statistics to convince the Food and Drug Administration that the drug should be tested in a larger Phase 2 trial. The agency required a summary of any and all side-effects there had been only a few and any deaths of patients on the study; thankfully, there had been none since the drug was reformulated. In a matter of days they needed to submit their findings for a prestigious meeting of clinical oncologists in June.

Posted in Biotech Stock | Tagged , , , | 1 Comment

January Top Insider Buys

Posted on January 31, 2010 by admin

Which insiders are selling and buying chunks of stocks? While trading penny stocks, insider open market trading is one of the best way to judge the stock movements.  

Below are lists of the top 10 open-market insider purchases and sales filed at the Securities and Exchange Commission in January 2010,  as ranked by dollar value. Company executives and directors are in the best position to assess the attractiveness of their firms’ shares, and here is how many of them are voting their wallets! Please note, however, that these are factual lists, not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction.

Company Name(Ticker) Filer Name Title(s) Shares brought Dollar Value Average PPS
Remec(REMC) S Muoio Co LLC Beneficial Owner 3,200,118 $2,720,100 $0.85
Remec(REMC) Morgan Stanley Beneficial Owner 1,640,000 $1,403,000 $0.86
Silicon Storage technology(SSTI) Dialectic Capital Mgt Officer 236,670 $609,653 $2.58
Spongetech Delivery Sys (SPNG) Pike Capital Partners LP Beneficial Owner 14,430,000 $572,600 $0.04
ATS (ATSC) Osmium Special Situations Fund Beneficial Owner 85,930 $213,304 $2.48
Searchmedia Holdings (IDI) Frost Phillip Md Et Al Beneficial Owner 25,000 $175,000 $7.00
Neostem (NBS) Myers Steven S Director 137,728 $150,124 $1.09
White Electronic Designs (WEDC) Kahn Brian Randall DirectorBeneficial Owner 23,074 $104,916 $4.55
Cogent Communications (CCOI) Margalit Erel N Director 7,140 $74,946 $10.50
Casual Male Retail (CMRG) Holtzman Seymour DirectorBeneficial Owner 20,800 $46,800 $2.25
Posted in Investing, Penny Stock | Tagged , , , , | 1 Comment